Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991577 | 0.83 | SMN1; SMN2 (0.41) | TSHRKMT2AMEN1TP53 | |
| SCHEMBL13186413 | 0.79 | GAA (0.46) | CYP4F2CYP4A11GAATSHRALDH1A1 | |
| SCHEMBL12768 | 0.79 | GAA (0.46) | CYP4F2CYP4A11GAATSHRALDH1A1 | |
| SCHEMBL13198913 | 0.79 | GAA (0.46) | CYP4F2CYP4A11GAATSHRALDH1A1 | |
| SCHEMBL436002 | 0.79 | TP53 (0.44) | CYP4F2CYP4A11TSHRALDH1A1ATM | |
| SCHEMBL954911 | 0.77 | TSHR (0.44) | CYP4F2CYP4A11GAATSHRALDH1A1 | |
| SCHEMBL772100 | 0.77 | TSHR (0.44) | CYP4F2CYP4A11GAATSHRALDH1A1 | |
| SCHEMBL28364104 | 0.77 | CYP2C19 (0.54) | CYP4F2CYP4A11GAATSHRALDH1A1 | |
| SCHEMBL3261975 | 0.76 | ALDH1A1 (0.38) | GAAALDH1A1ATM | |
| SCHEMBL3596666 | 0.76 | ALDH1A1 (0.38) | GAAALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | HTR4, HTR3B, HTR3A | CYP4F2 486/4885CYP4A11 318/4885GAA 3565/4885 |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CYP4F2 2534/4885CYP4A11 1479/4885GAA 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.